nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—ADRB2—prostate cancer	0.459	1	CbGaD
Droxidopa—ADRA1B—vas deferens—prostate cancer	0.0447	0.407	CbGeAlD
Droxidopa—ADRB3—prostate gland—prostate cancer	0.00694	0.0631	CbGeAlD
Droxidopa—Myocardial ischaemia—Abiraterone—prostate cancer	0.00692	0.0379	CcSEcCtD
Droxidopa—PAH—renal system—prostate cancer	0.00606	0.0551	CbGeAlD
Droxidopa—Blood pressure increased—Estrone—prostate cancer	0.00547	0.03	CcSEcCtD
Droxidopa—Blood pressure increased—Estradiol valerate/Dienogest—prostate cancer	0.00477	0.0262	CcSEcCtD
Droxidopa—Cardiac failure congestive—Estramustine—prostate cancer	0.00458	0.0251	CcSEcCtD
Droxidopa—ADRA1D—prostate gland—prostate cancer	0.00391	0.0355	CbGeAlD
Droxidopa—SLC16A10—prostate gland—prostate cancer	0.00348	0.0316	CbGeAlD
Droxidopa—DDC—renal system—prostate cancer	0.00345	0.0314	CbGeAlD
Droxidopa—Blood pressure increased—Ethinyl Estradiol—prostate cancer	0.0031	0.017	CcSEcCtD
Droxidopa—Urinary tract infection—Abiraterone—prostate cancer	0.00302	0.0166	CcSEcCtD
Droxidopa—Cardiac failure congestive—Bicalutamide—prostate cancer	0.00294	0.0161	CcSEcCtD
Droxidopa—ADRA1D—epithelium—prostate cancer	0.00287	0.0261	CbGeAlD
Droxidopa—ADRB1—prostate gland—prostate cancer	0.00284	0.0258	CbGeAlD
Droxidopa—Urinary tract infection—Nilutamide—prostate cancer	0.00276	0.0151	CcSEcCtD
Droxidopa—ADRA1B—renal system—prostate cancer	0.00272	0.0248	CbGeAlD
Droxidopa—ADRA1D—urethra—prostate cancer	0.00262	0.0238	CbGeAlD
Droxidopa—SLC16A10—epithelium—prostate cancer	0.00255	0.0232	CbGeAlD
Droxidopa—Blood pressure increased—Conjugated Estrogens—prostate cancer	0.00253	0.0139	CcSEcCtD
Droxidopa—Myocardial ischaemia—Estradiol—prostate cancer	0.00252	0.0138	CcSEcCtD
Droxidopa—Arrhythmia—Abiraterone—prostate cancer	0.00249	0.0137	CcSEcCtD
Droxidopa—Urinary tract infection—Degarelix—prostate cancer	0.00247	0.0135	CcSEcCtD
Droxidopa—Myocardial ischaemia—Mitoxantrone—prostate cancer	0.00234	0.0128	CcSEcCtD
Droxidopa—Urinary tract infection—Cabazitaxel—prostate cancer	0.00232	0.0127	CcSEcCtD
Droxidopa—ADRA1A—prostate gland—prostate cancer	0.00224	0.0204	CbGeAlD
Droxidopa—DDC—testis—prostate cancer	0.00223	0.0203	CbGeAlD
Droxidopa—ADRA2C—prostate gland—prostate cancer	0.00214	0.0194	CbGeAlD
Droxidopa—Hypertension—Abiraterone—prostate cancer	0.0021	0.0115	CcSEcCtD
Droxidopa—Cardiac failure congestive—Goserelin—prostate cancer	0.00204	0.0112	CcSEcCtD
Droxidopa—Arrhythmia—Degarelix—prostate cancer	0.00204	0.0112	CcSEcCtD
Droxidopa—Cardiac failure congestive—Conjugated Estrogens—prostate cancer	0.00202	0.0111	CcSEcCtD
Droxidopa—Blood pressure increased—Estradiol—prostate cancer	0.00202	0.0111	CcSEcCtD
Droxidopa—Urinary tract infection—Bicalutamide—prostate cancer	0.00199	0.0109	CcSEcCtD
Droxidopa—Syncope—Nilutamide—prostate cancer	0.00199	0.0109	CcSEcCtD
Droxidopa—Loss of consciousness—Nilutamide—prostate cancer	0.00195	0.0107	CcSEcCtD
Droxidopa—Arrhythmia—Cabazitaxel—prostate cancer	0.00192	0.0105	CcSEcCtD
Droxidopa—Hypertension—Nilutamide—prostate cancer	0.00192	0.0105	CcSEcCtD
Droxidopa—Hypertension—Flutamide—prostate cancer	0.00191	0.0105	CcSEcCtD
Droxidopa—Confusional state—Flutamide—prostate cancer	0.00182	0.00997	CcSEcCtD
Droxidopa—ADRA2C—seminal vesicle—prostate cancer	0.00181	0.0164	CbGeAlD
Droxidopa—Shock—Nilutamide—prostate cancer	0.00178	0.00977	CcSEcCtD
Droxidopa—Hypertension—Degarelix—prostate cancer	0.00171	0.00939	CcSEcCtD
Droxidopa—ADRA2A—prostate gland—prostate cancer	0.00171	0.0155	CbGeAlD
Droxidopa—Urinary tract infection—Ethinyl Estradiol—prostate cancer	0.00169	0.00924	CcSEcCtD
Droxidopa—ADRA1A—epithelium—prostate cancer	0.00165	0.015	CbGeAlD
Droxidopa—Arrhythmia—Bicalutamide—prostate cancer	0.00165	0.00902	CcSEcCtD
Droxidopa—Myocardial ischaemia—Docetaxel—prostate cancer	0.00162	0.00888	CcSEcCtD
Droxidopa—DDC—lymph node—prostate cancer	0.00162	0.0147	CbGeAlD
Droxidopa—Hypertension—Cabazitaxel—prostate cancer	0.00161	0.00884	CcSEcCtD
Droxidopa—Myocardial ischaemia—Capecitabine—prostate cancer	0.00157	0.0086	CcSEcCtD
Droxidopa—Confusional state—Cabazitaxel—prostate cancer	0.00154	0.00843	CcSEcCtD
Droxidopa—SLC16A10—testis—prostate cancer	0.00153	0.0139	CbGeAlD
Droxidopa—ADRA1A—renal system—prostate cancer	0.00153	0.0139	CbGeAlD
Droxidopa—Cardiac failure congestive—Mitoxantrone—prostate cancer	0.00151	0.00827	CcSEcCtD
Droxidopa—Feeling abnormal—Nilutamide—prostate cancer	0.00149	0.00819	CcSEcCtD
Droxidopa—Feeling abnormal—Flutamide—prostate cancer	0.00149	0.00815	CcSEcCtD
Droxidopa—ADRA2C—renal system—prostate cancer	0.00146	0.0133	CbGeAlD
Droxidopa—ADRA2A—seminal vesicle—prostate cancer	0.00144	0.0131	CbGeAlD
Droxidopa—Syncope—Bicalutamide—prostate cancer	0.00144	0.00788	CcSEcCtD
Droxidopa—ADRA2C—urethra—prostate cancer	0.00143	0.013	CbGeAlD
Droxidopa—Loss of consciousness—Bicalutamide—prostate cancer	0.00141	0.00772	CcSEcCtD
Droxidopa—Urinary tract infection—Goserelin—prostate cancer	0.00139	0.0076	CcSEcCtD
Droxidopa—Hypertension—Bicalutamide—prostate cancer	0.00138	0.00759	CcSEcCtD
Droxidopa—Feeling abnormal—Degarelix—prostate cancer	0.00133	0.00731	CcSEcCtD
Droxidopa—Confusional state—Bicalutamide—prostate cancer	0.00132	0.00723	CcSEcCtD
Droxidopa—Blood pressure increased—Docetaxel—prostate cancer	0.0013	0.00714	CcSEcCtD
Droxidopa—Dizziness—Estrone—prostate cancer	0.00129	0.00707	CcSEcCtD
Droxidopa—Shock—Bicalutamide—prostate cancer	0.00129	0.00706	CcSEcCtD
Droxidopa—Headache—Estramustine—prostate cancer	0.00128	0.00701	CcSEcCtD
Droxidopa—Blood pressure increased—Capecitabine—prostate cancer	0.00126	0.00691	CcSEcCtD
Droxidopa—Feeling abnormal—Cabazitaxel—prostate cancer	0.00126	0.00689	CcSEcCtD
Droxidopa—Cardiac failure congestive—Etoposide—prostate cancer	0.00125	0.00688	CcSEcCtD
Droxidopa—Headache—Estrone—prostate cancer	0.00122	0.0067	CcSEcCtD
Droxidopa—Nausea—Estramustine—prostate cancer	0.00121	0.00665	CcSEcCtD
Droxidopa—Dizziness—Nilutamide—prostate cancer	0.0012	0.00657	CcSEcCtD
Droxidopa—Dizziness—Flutamide—prostate cancer	0.00119	0.00654	CcSEcCtD
Droxidopa—Nausea—Estrone—prostate cancer	0.00116	0.00635	CcSEcCtD
Droxidopa—Arrhythmia—Goserelin—prostate cancer	0.00114	0.00627	CcSEcCtD
Droxidopa—ADRA2A—urethra—prostate cancer	0.00114	0.0104	CbGeAlD
Droxidopa—Headache—Nilutamide—prostate cancer	0.00114	0.00622	CcSEcCtD
Droxidopa—Arrhythmia—Conjugated Estrogens—prostate cancer	0.00113	0.00621	CcSEcCtD
Droxidopa—Headache—Flutamide—prostate cancer	0.00113	0.0062	CcSEcCtD
Droxidopa—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00113	0.00617	CcSEcCtD
Droxidopa—SLC16A10—lymph node—prostate cancer	0.00111	0.0101	CbGeAlD
Droxidopa—Methyldopa—COMT—prostate cancer	0.00111	0.123	CrCbGaD
Droxidopa—Urinary tract infection—Estradiol—prostate cancer	0.0011	0.00603	CcSEcCtD
Droxidopa—Feeling abnormal—Bicalutamide—prostate cancer	0.00108	0.00591	CcSEcCtD
Droxidopa—Nausea—Nilutamide—prostate cancer	0.00108	0.0059	CcSEcCtD
Droxidopa—Nausea—Flutamide—prostate cancer	0.00107	0.00587	CcSEcCtD
Droxidopa—Dizziness—Degarelix—prostate cancer	0.00107	0.00587	CcSEcCtD
Droxidopa—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00107	0.00585	CcSEcCtD
Droxidopa—SLC6A2—testis—prostate cancer	0.00106	0.00967	CbGeAlD
Droxidopa—Cardiac failure congestive—Docetaxel—prostate cancer	0.00104	0.00572	CcSEcCtD
Droxidopa—Urinary tract infection—Mitoxantrone—prostate cancer	0.00102	0.00562	CcSEcCtD
Droxidopa—Headache—Degarelix—prostate cancer	0.00101	0.00556	CcSEcCtD
Droxidopa—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00101	0.00554	CcSEcCtD
Droxidopa—Dizziness—Cabazitaxel—prostate cancer	0.00101	0.00553	CcSEcCtD
Droxidopa—Syncope—Conjugated Estrogens—prostate cancer	0.000991	0.00543	CcSEcCtD
Droxidopa—Loss of consciousness—Conjugated Estrogens—prostate cancer	0.000971	0.00532	CcSEcCtD
Droxidopa—Hypertension—Goserelin—prostate cancer	0.000963	0.00528	CcSEcCtD
Droxidopa—Nausea—Degarelix—prostate cancer	0.000962	0.00527	CcSEcCtD
Droxidopa—Headache—Cabazitaxel—prostate cancer	0.000956	0.00524	CcSEcCtD
Droxidopa—ADRA2C—testis—prostate cancer	0.000942	0.00857	CbGeAlD
Droxidopa—Confusional state—Goserelin—prostate cancer	0.000918	0.00503	CcSEcCtD
Droxidopa—Feeling abnormal—Ethinyl Estradiol—prostate cancer	0.000911	0.005	CcSEcCtD
Droxidopa—Nausea—Cabazitaxel—prostate cancer	0.000906	0.00497	CcSEcCtD
Droxidopa—Cardiac failure congestive—Prednisone—prostate cancer	0.000899	0.00493	CcSEcCtD
Droxidopa—Shock—Goserelin—prostate cancer	0.000896	0.00491	CcSEcCtD
Droxidopa—Aminosalicylic Acid—MPO—prostate cancer	0.000895	0.0997	CrCbGaD
Droxidopa—Shock—Conjugated Estrogens—prostate cancer	0.000887	0.00486	CcSEcCtD
Droxidopa—Dizziness—Bicalutamide—prostate cancer	0.000865	0.00474	CcSEcCtD
Droxidopa—Arrhythmia—Mitoxantrone—prostate cancer	0.000845	0.00463	CcSEcCtD
Droxidopa—Headache—Bicalutamide—prostate cancer	0.00082	0.00449	CcSEcCtD
Droxidopa—Isoetarine—ADRB2—prostate cancer	0.000811	0.0903	CrCbGaD
Droxidopa—Syncope—Estradiol—prostate cancer	0.000793	0.00435	CcSEcCtD
Droxidopa—Nausea—Bicalutamide—prostate cancer	0.000777	0.00426	CcSEcCtD
Droxidopa—Loss of consciousness—Estradiol—prostate cancer	0.000777	0.00426	CcSEcCtD
Droxidopa—SLC6A2—lymph node—prostate cancer	0.000771	0.00701	CbGeAlD
Droxidopa—Hypertension—Estradiol—prostate cancer	0.000763	0.00418	CcSEcCtD
Droxidopa—ADRA2A—testis—prostate cancer	0.000752	0.00684	CbGeAlD
Droxidopa—Feeling abnormal—Goserelin—prostate cancer	0.00075	0.00411	CcSEcCtD
Droxidopa—Dizziness—Ethinyl Estradiol—prostate cancer	0.000731	0.00401	CcSEcCtD
Droxidopa—Confusional state—Estradiol—prostate cancer	0.000728	0.00399	CcSEcCtD
Droxidopa—Hypertension—Mitoxantrone—prostate cancer	0.000711	0.0039	CcSEcCtD
Droxidopa—Shock—Estradiol—prostate cancer	0.00071	0.00389	CcSEcCtD
Droxidopa—Cardiac failure congestive—Epirubicin—prostate cancer	0.000703	0.00386	CcSEcCtD
Droxidopa—Mesalazine—MPO—prostate cancer	0.000702	0.0782	CrCbGaD
Droxidopa—Headache—Ethinyl Estradiol—prostate cancer	0.000693	0.0038	CcSEcCtD
Droxidopa—Urinary tract infection—Capecitabine—prostate cancer	0.000686	0.00376	CcSEcCtD
Droxidopa—ADRA2C—lymph node—prostate cancer	0.000683	0.00621	CbGeAlD
Droxidopa—Norepinephrine—SLC22A3—prostate cancer	0.000681	0.0759	CrCbGaD
Droxidopa—Confusional state—Mitoxantrone—prostate cancer	0.000678	0.00372	CcSEcCtD
Droxidopa—Shock—Mitoxantrone—prostate cancer	0.000662	0.00363	CcSEcCtD
Droxidopa—Nausea—Ethinyl Estradiol—prostate cancer	0.000657	0.0036	CcSEcCtD
Droxidopa—Cardiac failure congestive—Doxorubicin—prostate cancer	0.000651	0.00357	CcSEcCtD
Droxidopa—Dopamine—SLC22A3—prostate cancer	0.000633	0.0705	CrCbGaD
Droxidopa—Loss of consciousness—Etoposide—prostate cancer	0.000602	0.0033	CcSEcCtD
Droxidopa—Dizziness—Goserelin—prostate cancer	0.000602	0.0033	CcSEcCtD
Droxidopa—Dizziness—Conjugated Estrogens—prostate cancer	0.000596	0.00327	CcSEcCtD
Droxidopa—Feeling abnormal—Estradiol—prostate cancer	0.000595	0.00326	CcSEcCtD
Droxidopa—Hypertension—Etoposide—prostate cancer	0.000592	0.00324	CcSEcCtD
Droxidopa—Arrhythmia—Docetaxel—prostate cancer	0.000584	0.0032	CcSEcCtD
Droxidopa—Headache—Goserelin—prostate cancer	0.00057	0.00313	CcSEcCtD
Droxidopa—Arrhythmia—Capecitabine—prostate cancer	0.000566	0.0031	CcSEcCtD
Droxidopa—Headache—Conjugated Estrogens—prostate cancer	0.000565	0.0031	CcSEcCtD
Droxidopa—Confusional state—Etoposide—prostate cancer	0.000564	0.00309	CcSEcCtD
Droxidopa—Feeling abnormal—Mitoxantrone—prostate cancer	0.000554	0.00304	CcSEcCtD
Droxidopa—ADRA2A—lymph node—prostate cancer	0.000545	0.00496	CbGeAlD
Droxidopa—Dopamine—COMT—prostate cancer	0.000541	0.0603	CrCbGaD
Droxidopa—Nausea—Goserelin—prostate cancer	0.000541	0.00296	CcSEcCtD
Droxidopa—Nausea—Conjugated Estrogens—prostate cancer	0.000536	0.00294	CcSEcCtD
Droxidopa—Syncope—Docetaxel—prostate cancer	0.000511	0.0028	CcSEcCtD
Droxidopa—Arrhythmia—Prednisone—prostate cancer	0.000504	0.00276	CcSEcCtD
Droxidopa—Loss of consciousness—Docetaxel—prostate cancer	0.000501	0.00274	CcSEcCtD
Droxidopa—Syncope—Capecitabine—prostate cancer	0.000495	0.00271	CcSEcCtD
Droxidopa—Hypertension—Docetaxel—prostate cancer	0.000492	0.00269	CcSEcCtD
Droxidopa—Norepinephrine—SLC22A1—prostate cancer	0.000489	0.0544	CrCbGaD
Droxidopa—Loss of consciousness—Capecitabine—prostate cancer	0.000485	0.00266	CcSEcCtD
Droxidopa—Urinary tract infection—Epirubicin—prostate cancer	0.000478	0.00262	CcSEcCtD
Droxidopa—Dizziness—Estradiol—prostate cancer	0.000477	0.00262	CcSEcCtD
Droxidopa—Hypertension—Capecitabine—prostate cancer	0.000476	0.00261	CcSEcCtD
Droxidopa—Confusional state—Docetaxel—prostate cancer	0.000469	0.00257	CcSEcCtD
Droxidopa—Feeling abnormal—Etoposide—prostate cancer	0.000461	0.00253	CcSEcCtD
Droxidopa—Shock—Docetaxel—prostate cancer	0.000457	0.00251	CcSEcCtD
Droxidopa—Dopamine—SLC22A1—prostate cancer	0.000454	0.0506	CrCbGaD
Droxidopa—Confusional state—Capecitabine—prostate cancer	0.000454	0.00249	CcSEcCtD
Droxidopa—Headache—Estradiol—prostate cancer	0.000452	0.00248	CcSEcCtD
Droxidopa—Epinephrine—SLC22A1—prostate cancer	0.000443	0.0494	CrCbGaD
Droxidopa—Shock—Capecitabine—prostate cancer	0.000443	0.00243	CcSEcCtD
Droxidopa—Urinary tract infection—Doxorubicin—prostate cancer	0.000442	0.00242	CcSEcCtD
Droxidopa—Syncope—Prednisone—prostate cancer	0.00044	0.00241	CcSEcCtD
Droxidopa—Loss of consciousness—Prednisone—prostate cancer	0.000432	0.00237	CcSEcCtD
Droxidopa—Nausea—Estradiol—prostate cancer	0.000429	0.00235	CcSEcCtD
Droxidopa—Hypertension—Prednisone—prostate cancer	0.000424	0.00232	CcSEcCtD
Droxidopa—Headache—Mitoxantrone—prostate cancer	0.000421	0.00231	CcSEcCtD
Droxidopa—Nausea—Mitoxantrone—prostate cancer	0.000399	0.00219	CcSEcCtD
Droxidopa—Shock—Prednisone—prostate cancer	0.000394	0.00216	CcSEcCtD
Droxidopa—Arrhythmia—Epirubicin—prostate cancer	0.000394	0.00216	CcSEcCtD
Droxidopa—Feeling abnormal—Docetaxel—prostate cancer	0.000383	0.0021	CcSEcCtD
Droxidopa—Feeling abnormal—Capecitabine—prostate cancer	0.000371	0.00203	CcSEcCtD
Droxidopa—Dizziness—Etoposide—prostate cancer	0.00037	0.00203	CcSEcCtD
Droxidopa—Arrhythmia—Doxorubicin—prostate cancer	0.000365	0.002	CcSEcCtD
Droxidopa—Headache—Etoposide—prostate cancer	0.00035	0.00192	CcSEcCtD
Droxidopa—Syncope—Epirubicin—prostate cancer	0.000345	0.00189	CcSEcCtD
Droxidopa—Loss of consciousness—Epirubicin—prostate cancer	0.000338	0.00185	CcSEcCtD
Droxidopa—Isoprenaline—ADRB2—prostate cancer	0.000337	0.0375	CrCbGaD
Droxidopa—Aminosalicylic Acid—PTGS2—prostate cancer	0.000335	0.0374	CrCbGaD
Droxidopa—Nausea—Etoposide—prostate cancer	0.000332	0.00182	CcSEcCtD
Droxidopa—Hypertension—Epirubicin—prostate cancer	0.000332	0.00182	CcSEcCtD
Droxidopa—Feeling abnormal—Prednisone—prostate cancer	0.00033	0.00181	CcSEcCtD
Droxidopa—Syncope—Doxorubicin—prostate cancer	0.000319	0.00175	CcSEcCtD
Droxidopa—Confusional state—Epirubicin—prostate cancer	0.000316	0.00173	CcSEcCtD
Droxidopa—Loss of consciousness—Doxorubicin—prostate cancer	0.000312	0.00171	CcSEcCtD
Droxidopa—Norepinephrine—ADRB2—prostate cancer	0.000312	0.0347	CrCbGaD
Droxidopa—Shock—Epirubicin—prostate cancer	0.000308	0.00169	CcSEcCtD
Droxidopa—Dizziness—Docetaxel—prostate cancer	0.000307	0.00168	CcSEcCtD
Droxidopa—Hypertension—Doxorubicin—prostate cancer	0.000307	0.00168	CcSEcCtD
Droxidopa—Dizziness—Capecitabine—prostate cancer	0.000298	0.00163	CcSEcCtD
Droxidopa—Confusional state—Doxorubicin—prostate cancer	0.000293	0.0016	CcSEcCtD
Droxidopa—Headache—Docetaxel—prostate cancer	0.000291	0.0016	CcSEcCtD
Droxidopa—Isoprenaline—CYP1A1—prostate cancer	0.000289	0.0321	CrCbGaD
Droxidopa—Shock—Doxorubicin—prostate cancer	0.000285	0.00156	CcSEcCtD
Droxidopa—Epinephrine—ADRB2—prostate cancer	0.000283	0.0315	CrCbGaD
Droxidopa—Headache—Capecitabine—prostate cancer	0.000282	0.00155	CcSEcCtD
Droxidopa—Nausea—Docetaxel—prostate cancer	0.000276	0.00151	CcSEcCtD
Droxidopa—Nausea—Capecitabine—prostate cancer	0.000267	0.00147	CcSEcCtD
Droxidopa—Dizziness—Prednisone—prostate cancer	0.000265	0.00145	CcSEcCtD
Droxidopa—Mesalazine—PTGS2—prostate cancer	0.000263	0.0293	CrCbGaD
Droxidopa—Feeling abnormal—Epirubicin—prostate cancer	0.000258	0.00142	CcSEcCtD
Droxidopa—Headache—Prednisone—prostate cancer	0.000251	0.00138	CcSEcCtD
Droxidopa—Dopamine—CYP2C19—prostate cancer	0.000249	0.0278	CrCbGaD
Droxidopa—Feeling abnormal—Doxorubicin—prostate cancer	0.000239	0.00131	CcSEcCtD
Droxidopa—Nausea—Prednisone—prostate cancer	0.000238	0.0013	CcSEcCtD
Droxidopa—Dizziness—Epirubicin—prostate cancer	0.000207	0.00114	CcSEcCtD
Droxidopa—Headache—Epirubicin—prostate cancer	0.000196	0.00108	CcSEcCtD
Droxidopa—Dizziness—Doxorubicin—prostate cancer	0.000192	0.00105	CcSEcCtD
Droxidopa—Nausea—Epirubicin—prostate cancer	0.000186	0.00102	CcSEcCtD
Droxidopa—Headache—Doxorubicin—prostate cancer	0.000182	0.000996	CcSEcCtD
Droxidopa—Nausea—Doxorubicin—prostate cancer	0.000172	0.000944	CcSEcCtD
Droxidopa—Epinephrine—CYP3A4—prostate cancer	0.000155	0.0172	CrCbGaD
Droxidopa—ADRB3—Signaling Pathways—TP53—prostate cancer	5.67e-06	2.37e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ERBB2—prostate cancer	5.65e-06	2.36e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	5.65e-06	2.36e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NOS3—prostate cancer	5.63e-06	2.35e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCND1—prostate cancer	5.6e-06	2.34e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APC—prostate cancer	5.59e-06	2.34e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	5.59e-06	2.34e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	5.58e-06	2.33e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	5.58e-06	2.33e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—JAK2—prostate cancer	5.56e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—NOS3—prostate cancer	5.55e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	5.55e-06	2.32e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IRS1—prostate cancer	5.53e-06	2.31e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—EGF—prostate cancer	5.53e-06	2.31e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IGF1—prostate cancer	5.51e-06	2.3e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	5.49e-06	2.29e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CXCL8—prostate cancer	5.48e-06	2.29e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—JAK2—prostate cancer	5.47e-06	2.28e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PTEN—prostate cancer	5.45e-06	2.28e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	5.45e-06	2.28e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MMP9—prostate cancer	5.44e-06	2.27e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	5.43e-06	2.27e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MDM2—prostate cancer	5.42e-06	2.27e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	5.42e-06	2.26e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PTEN—prostate cancer	5.41e-06	2.26e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	5.37e-06	2.24e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CXCL8—prostate cancer	5.36e-06	2.24e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	5.36e-06	2.24e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	5.35e-06	2.24e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	5.35e-06	2.23e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MDM2—prostate cancer	5.34e-06	2.23e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	5.33e-06	2.23e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	5.3e-06	2.22e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—INS—prostate cancer	5.3e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	5.29e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	5.29e-06	2.21e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	5.28e-06	2.2e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	5.28e-06	2.2e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	5.26e-06	2.2e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	5.24e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CASP3—prostate cancer	5.24e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	5.24e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL2—prostate cancer	5.24e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	5.23e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	5.23e-06	2.19e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—IL6—prostate cancer	5.21e-06	2.18e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—EP300—prostate cancer	5.2e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CASP3—prostate cancer	5.2e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	5.19e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL2—prostate cancer	5.19e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	5.19e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—IL6—prostate cancer	5.19e-06	2.17e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	5.18e-06	2.16e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	5.18e-06	2.16e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—IL6—prostate cancer	5.16e-06	2.16e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—EP300—prostate cancer	5.16e-06	2.15e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CASP3—prostate cancer	5.13e-06	2.14e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CB—prostate cancer	5.13e-06	2.14e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL2—prostate cancer	5.12e-06	2.14e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IGF1—prostate cancer	5.12e-06	2.14e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCND1—prostate cancer	5.1e-06	2.13e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—IL6—prostate cancer	5.1e-06	2.13e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	5.1e-06	2.13e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTGS2—prostate cancer	5.08e-06	2.12e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	5.07e-06	2.12e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—FGF2—prostate cancer	5.07e-06	2.12e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCND1—prostate cancer	5.06e-06	2.11e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	5.05e-06	2.11e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—SRC—prostate cancer	5.01e-06	2.1e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	5.01e-06	2.09e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NOS3—prostate cancer	5e-06	2.09e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCND1—prostate cancer	4.99e-06	2.09e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	4.99e-06	2.09e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MMP9—prostate cancer	4.96e-06	2.07e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	4.95e-06	2.07e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	4.95e-06	2.07e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	4.94e-06	2.07e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	4.94e-06	2.06e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PTEN—prostate cancer	4.93e-06	2.06e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	4.92e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MMP9—prostate cancer	4.91e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	4.9e-06	2.05e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	4.89e-06	2.04e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	4.88e-06	2.04e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PTEN—prostate cancer	4.88e-06	2.04e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	4.87e-06	2.04e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	4.87e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	4.86e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—JAK2—prostate cancer	4.86e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CASP3—prostate cancer	4.85e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MMP9—prostate cancer	4.85e-06	2.03e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL2—prostate cancer	4.85e-06	2.02e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—STAT3—prostate cancer	4.84e-06	2.02e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	4.83e-06	2.02e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—IL6—prostate cancer	4.82e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	4.82e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PTEN—prostate cancer	4.82e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	4.81e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—AKT1—prostate cancer	4.81e-06	2.01e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—AKT1—prostate cancer	4.78e-06	2e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CASP3—prostate cancer	4.78e-06	2e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL2—prostate cancer	4.77e-06	1.99e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	4.76e-06	1.99e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	4.76e-06	1.99e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—IL6—prostate cancer	4.75e-06	1.98e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MDM2—prostate cancer	4.74e-06	1.98e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCND1—prostate cancer	4.72e-06	1.97e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—FGF2—prostate cancer	4.71e-06	1.97e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—AKT1—prostate cancer	4.7e-06	1.96e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—EP300—prostate cancer	4.7e-06	1.96e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	4.68e-06	1.95e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	4.67e-06	1.95e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—EP300—prostate cancer	4.66e-06	1.95e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCND1—prostate cancer	4.65e-06	1.94e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NOS3—prostate cancer	4.64e-06	1.94e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	4.61e-06	1.93e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	4.6e-06	1.92e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—EP300—prostate cancer	4.6e-06	1.92e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MMP9—prostate cancer	4.59e-06	1.92e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	4.57e-06	1.91e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SRC—prostate cancer	4.57e-06	1.91e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PTEN—prostate cancer	4.56e-06	1.91e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SRC—prostate cancer	4.53e-06	1.89e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MMP9—prostate cancer	4.51e-06	1.89e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—JAK2—prostate cancer	4.51e-06	1.89e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	4.5e-06	1.88e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MYC—prostate cancer	4.49e-06	1.88e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PTEN—prostate cancer	4.49e-06	1.87e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	4.48e-06	1.87e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SRC—prostate cancer	4.47e-06	1.87e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VEGFA—prostate cancer	4.45e-06	1.86e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	4.45e-06	1.86e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	4.43e-06	1.85e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PTEN—prostate cancer	4.43e-06	1.85e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	4.42e-06	1.85e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	4.41e-06	1.84e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—STAT3—prostate cancer	4.41e-06	1.84e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MDM2—prostate cancer	4.41e-06	1.84e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—EGFR—prostate cancer	4.4e-06	1.84e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	4.38e-06	1.83e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—STAT3—prostate cancer	4.37e-06	1.82e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VEGFA—prostate cancer	4.35e-06	1.82e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—EP300—prostate cancer	4.35e-06	1.82e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	4.34e-06	1.81e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	4.33e-06	1.81e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—STAT3—prostate cancer	4.31e-06	1.8e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	4.29e-06	1.79e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	4.28e-06	1.79e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—EP300—prostate cancer	4.28e-06	1.79e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CASP3—prostate cancer	4.24e-06	1.77e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL2—prostate cancer	4.24e-06	1.77e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SRC—prostate cancer	4.23e-06	1.77e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—EP300—prostate cancer	4.22e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—IL6—prostate cancer	4.22e-06	1.76e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SRC—prostate cancer	4.16e-06	1.74e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KRAS—prostate cancer	4.15e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCND1—prostate cancer	4.13e-06	1.73e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	4.12e-06	1.72e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	4.12e-06	1.72e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MYC—prostate cancer	4.09e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	4.09e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TGFB1—prostate cancer	4.08e-06	1.71e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—STAT3—prostate cancer	4.08e-06	1.7e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MYC—prostate cancer	4.06e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	4.05e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	4.05e-06	1.69e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	4.02e-06	1.68e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—STAT3—prostate cancer	4.01e-06	1.68e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MMP9—prostate cancer	4.01e-06	1.68e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MYC—prostate cancer	4.01e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—EGFR—prostate cancer	4e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	4e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TGFB1—prostate cancer	4e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTEN—prostate cancer	3.99e-06	1.67e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	3.98e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—EGFR—prostate cancer	3.97e-06	1.66e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CASP3—prostate cancer	3.94e-06	1.65e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL2—prostate cancer	3.94e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—EGFR—prostate cancer	3.92e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—IL6—prostate cancer	3.92e-06	1.64e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	3.89e-06	1.62e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—PIK3CA—prostate cancer	3.85e-06	1.61e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCND1—prostate cancer	3.84e-06	1.6e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	3.81e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—EP300—prostate cancer	3.8e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	3.8e-06	1.59e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MYC—prostate cancer	3.79e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KRAS—prostate cancer	3.78e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	3.78e-06	1.58e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KRAS—prostate cancer	3.75e-06	1.57e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MYC—prostate cancer	3.73e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MMP9—prostate cancer	3.73e-06	1.56e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	3.72e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	3.71e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—EGFR—prostate cancer	3.71e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTEN—prostate cancer	3.7e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KRAS—prostate cancer	3.7e-06	1.55e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SRC—prostate cancer	3.7e-06	1.54e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TP53—prostate cancer	3.69e-06	1.54e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—EGFR—prostate cancer	3.65e-06	1.52e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	3.61e-06	1.51e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	3.6e-06	1.5e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—STAT3—prostate cancer	3.57e-06	1.49e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—EP300—prostate cancer	3.53e-06	1.48e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KRAS—prostate cancer	3.5e-06	1.46e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	3.48e-06	1.45e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KRAS—prostate cancer	3.45e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	3.44e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SRC—prostate cancer	3.43e-06	1.44e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	3.4e-06	1.42e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—IL6—prostate cancer	3.38e-06	1.41e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TP53—prostate cancer	3.36e-06	1.4e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	3.35e-06	1.4e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TP53—prostate cancer	3.33e-06	1.39e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MYC—prostate cancer	3.31e-06	1.38e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—STAT3—prostate cancer	3.31e-06	1.38e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	3.3e-06	1.38e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TP53—prostate cancer	3.29e-06	1.37e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—EGFR—prostate cancer	3.24e-06	1.35e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	3.22e-06	1.34e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	3.17e-06	1.32e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AKT1—prostate cancer	3.14e-06	1.31e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—PIK3CA—prostate cancer	3.12e-06	1.31e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AKT1—prostate cancer	3.12e-06	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TP53—prostate cancer	3.11e-06	1.3e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MYC—prostate cancer	3.08e-06	1.29e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—IL6—prostate cancer	3.08e-06	1.29e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	3.07e-06	1.28e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TP53—prostate cancer	3.06e-06	1.28e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KRAS—prostate cancer	3.06e-06	1.28e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—IL6—prostate cancer	3.05e-06	1.27e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—IL6—prostate cancer	3.01e-06	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—EGFR—prostate cancer	3.01e-06	1.26e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—IL6—prostate cancer	2.85e-06	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KRAS—prostate cancer	2.84e-06	1.19e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT1—prostate cancer	2.84e-06	1.19e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT1—prostate cancer	2.81e-06	1.18e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	2.81e-06	1.17e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—IL6—prostate cancer	2.8e-06	1.17e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.78e-06	1.16e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TP53—prostate cancer	2.72e-06	1.14e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT1—prostate cancer	2.63e-06	1.1e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.61e-06	1.09e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT1—prostate cancer	2.59e-06	1.08e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AKT1—prostate cancer	2.55e-06	1.07e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.53e-06	1.06e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—IL6—prostate cancer	2.49e-06	1.04e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—IL6—prostate cancer	2.31e-06	9.67e-06	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT1—prostate cancer	2.3e-06	9.6e-06	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT1—prostate cancer	2.13e-06	8.92e-06	CbGpPWpGaD
